Acelyrin
在场
高管
查看带有其 18 名主要高管的组织结构图
Acelyrin 搜索最多的简介
高管在Acelyrin变化
- Melanie Gloria, Chief Operating Officer, 已经离开公司 (新闻发布的2024十一月27号).
- Shao-Lee Lin, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024五月10号).
- Mina Kim 曾任 Chief Legal and Administrative Officer, 现升职为 Chief Executive Officer and Director (新闻发布的2024五月10号).
创建提醒
跟踪 Acelyrin 的高管变动
生物技术
Acelyrin 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Acelyrin 的最新新闻稿
- An interview with ACELYRIN’s Chief Operating Officer Melanie Gloria
- News Center | ACELYRIN
- Shao-Lee Lin, MD, PhD - Courageous Caring in the Age of COVID
- Dr. Shao-Lee Lin and Bob Carey talk strategy and more at ACELYRIN
- ACELYRIN | An Innovative Biopharma Company
- Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
- ACELYRIN, INC. Adds Two Veteran C-suite Leaders
- ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Funct
- ACELYRIN, INC. to Present at Upcoming Investor Conferences
- ACELYRIN | $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep
- View more press releases Close
通过电子邮件
